AveXis Inc (NASDAQ:AVXS)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued on Friday. They presently have a $100.00 price objective on the stock. Chardan Capital’s price objective points to a potential upside of 25.39% from the company’s current price.
Other equities research analysts have also recently issued research reports about the stock. Jefferies Group LLC lifted their price target on shares of AveXis from $79.00 to $92.00 and gave the stock a “buy” rating in a research report on Friday. BMO Capital Markets reiterated an “outperform” rating and set a $95.00 price target (up previously from $85.00) on shares of AveXis in a research report on Friday. Goldman Sachs Group Inc lifted their price target on shares of AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, February 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $85.33.
Shares of AveXis (NASDAQ:AVXS) opened at 79.75 on Friday. AveXis has a 12 month low of $20.51 and a 12 month high of $85.98. The stock’s market cap is $2.21 billion. The company has a 50 day moving average of $62.69 and a 200 day moving average of $53.26.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings results on Thursday, March 16th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.12. During the same period in the prior year, the business posted ($1.82) EPS. Equities research analysts expect that AveXis will post ($3.93) earnings per share for the current fiscal year.
Your IP Address:
Several large investors have recently modified their holdings of AVXS. JPMorgan Chase & Co. boosted its stake in shares of AveXis by 7.1% in the third quarter. JPMorgan Chase & Co. now owns 37,150 shares of the company’s stock valued at $1,531,000 after buying an additional 2,475 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of AveXis by 1.9% in the third quarter. Jennison Associates LLC now owns 183,145 shares of the company’s stock valued at $7,547,000 after buying an additional 3,362 shares in the last quarter. A.R.T. Advisors LLC boosted its stake in shares of AveXis by 68.8% in the fourth quarter. A.R.T. Advisors LLC now owns 10,800 shares of the company’s stock valued at $515,000 after buying an additional 4,400 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in shares of AveXis during the fourth quarter valued at approximately $277,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of AveXis during the fourth quarter valued at approximately $640,000. Institutional investors own 68.31% of the company’s stock.
AveXis Company Profile
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024280/avexis-inc-avxs-rating-reiterated-by-chardan-capital.html
Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.